TOPOLOGY: A phase II study to evaluate the efficacy and toxicities of PLX038, in patients with locally advanced or metastatic triple-negative breast cancer

被引：0
|
作者：
Cabel, Luc
Loirat, Delphine
Babau, Jerome Martin
Bello, Diana
Pierga, Jean-Yves
Lerebours, Florence
Ezzili, Cyrine
Berger, Frederique
Bidard, Francois Clement
机构：
[1] Inst Curie, Paris, France
[2] Inst Curie, St Cloud, France
[3] Inst Curie, Med Oncol Dept & D3i, Paris, France
[4] Hop Prive Cotes Armor, Plerin, France
[5] Inst Curie, Med Oncol Dept, St Cloud, France
[6] Inst Curie Paris, Paris, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS1142
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer
    O'Shaughnessy, Joyce
    Brufsky, Adam
    Rugo, Hope S.
    Tolaney, Sara M.
    Punie, Kevin
    Sardesai, Sagar
    Hamilton, Erika
    Loirat, Delphine
    Traina, Tiffany
    Leon-Ferre, Roberto
    Hurvitz, Sara A.
    Kalinsky, Kevin
    Bardia, Aditya
    Henry, Stephanie
    Mayer, Ingrid
    Zhu, Yanni
    Phan, See
    Cortes, Javier
    BREAST CANCER RESEARCH AND TREATMENT, 2022, 195 (02) : 127 - 139
  • [42] Apatinib plus etoposide in pretreated patients with advanced triple-negative breast cancer: a phase II trial
    Mengru Cao
    Hailing Lu
    Shi Yan
    Hui Pang
    Lichun Sun
    Chunhong Li
    Xuesong Chen
    Wei Liu
    Jing Hu
    Jian Huang
    Ying Xing
    Ningzhi Zhang
    Yingqi Chen
    Ting He
    Danni Zhao
    Yuanyuan Sun
    Lin Zhao
    Xiaomeng Liu
    Li Cai
    BMC Cancer, 23
  • [43] Apatinib plus etoposide in pretreated patients with advanced triple-negative breast cancer: a phase II trial
    Cao, Mengru
    Lu, Hailing
    Yan, Shi
    Pang, Hui
    Sun, Lichun
    Li, Chunhong
    Chen, Xuesong
    Liu, Wei
    Hu, Jing
    Huang, Jian
    Xing, Ying
    Zhang, Ningzhi
    Chen, Yingqi
    He, Ting
    Zhao, Danni
    Sun, Yuanyuan
    Zhao, Lin
    Liu, Xiaomeng
    Cai, Li
    BMC CANCER, 2023, 23 (01)
  • [44] Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer
    Tolaney, Sara M.
    Kalinsky, Kevin
    Kaklamani, Virginia
    Savulsky, Claudio
    Olivo, Martin
    Aktan, Gursel
    Kaufman, Peter A.
    Xing, Dongyuan
    Almonte, Ana
    Misir, Soamnauth
    Karantza, Vassiliki
    Diab, Sami
    CANCER RESEARCH, 2018, 78 (04)
  • [45] Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer
    Tolaney, Sara M.
    Kalinsky, Kevin
    Kaklamani, Virginia
    Savulsky, Claudio
    Olivo, Martin
    Aktan, Gursel
    Kaufman, Peter A.
    Xing, Dongyuan
    Almonte, Ana
    Misir, Soamnauth
    Karantza, Vassiliki
    Young, Louise
    Diab, Sami
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 176 - 176
  • [46] Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer
    Tolaney, S.
    Savulsky, C.
    Aktan, G.
    Xing, D.
    Almonte, A.
    Karantza, V.
    Diab, S.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S16 - S16
  • [47] Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer
    Tolaney, S.
    Savulsky, C.
    Aktan, G.
    Xing, D.
    Almonte, A.
    Karantza, V.
    Diab, S.
    CANCER RESEARCH, 2017, 77
  • [48] A phase I/II trial evaluating the safety and efficacy of eribulin in combination with copanlisib in patients with metastatic triple-negative breast cancer (TNBC)
    Bagegni, Nusayba Ali
    Nehring, Leslie
    Anderson, Jill
    Haas, Brittney
    Luo, Jingqin
    Trivedi, Meghna S.
    Kennedy, Laura Carpin
    Bhave, Manali A.
    Daily, Karen Colleen
    Razaq, Wajeeha
    Lu, Yiling
    Wang, Wei-Lien
    Wulf, Gerburg M.
    Said, Rabih
    Ma, Cynthia X.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [49] Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretrnted patients with metastatic triple-negative breast cancer
    Hu, Xichun
    Zhang, Jian
    Xu, Binghe
    Jiang, Zefei
    Ragaz, Joseph
    Tong, Zhongsheng
    Zhang, Qingyuan
    Wang, Xiaojia
    Feng, Jifeng
    Pang, Danmei
    Fan, Minhao
    Li, Jin
    Wang, Biyun
    Wang, Zhonghua
    Zhang, Qunling
    Sun, Si
    Liao, Chunmei
    INTERNATIONAL JOURNAL OF CANCER, 2014, 135 (08) : 1961 - 1969
  • [50] Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer
    Daniel G. Stover
    Carlos R. Gil Del Alcazar
    Jane Brock
    Hao Guo
    Beth Overmoyer
    Justin Balko
    Qiong Xu
    Aditya Bardia
    Sara M. Tolaney
    Rebecca Gelman
    Maxwell Lloyd
    Yu Wang
    Yaomin Xu
    Franziska Michor
    Vivian Wang
    Eric P. Winer
    Kornelia Polyak
    Nancy U. Lin
    npj Breast Cancer, 4
12345